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ABSTRACT 
OBJECTIVE: 
Primary Objective:  
To determine the maternal and fetal outcomes that result from symptomatic urinary 
tract infection in pregnancy. 
METHODS: 
This is a cross sectional study which was done in the department of General Medicine and 
Obstetrics and Gynecology at Christian Medical College Vellore. Pregnant women who 
were booked in CMC for their antenatal care were included in the study. Pregnant women 
with symptomatic urinary tract infection with significant growth in urinary culture were 
taken as cases and others were taken as controls. Maternal and fetal outcomes were 
assessed at delivery. Comparison of quantitative variables were done using independent t-
test or Wilcoxon rank sum test. Comparison of categorical variables were done using 
Fisher’s Exact test. All significant variables were analysed using Logistic regression. 
RESULTS AND CONCLUSIONS:  
On univariate analysis, preterm premature rupture of membranes was more among the case 
than controls with OR of 2.697 which was statistically significant (95% CI- 1.423- 5.11, 
p=0.001) Preterm delivery and post-partum sepsis were also statistically significant with 
OR of 3.162 and 3.972 respectively. Intrauterine growth restriction, Neonatal ICU 
admission and low birth weight were more among the infants born to cases than controls 
which was statistically significant with OR of 1.697, 4.406, and 2.290 respectively. 
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Primigravida, multifetal pregnancy, low maternal education, past history of catheterization, 
urinary tract infection, and anemia were statistically significant risk factors for the 
development of urinary tract infection.  
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INTRODUCTION 
Urinary tract infection (UTI) is a widely prevalent problem in developing countries like 
India. The prevalence of urinary tract infection is higher in the pregnant women due to the 
physiological changes that occur in the urinary tract during pregnancy. This leads to 
adverse maternal and fetal outcomes, which could have been avoided by preventing the 
urinary tract infection. Despite increase in hospital based ante-natal checkups and more 
deliveries in hospital than at home which has significantly reduced maternal and fetal 
morbidity and mortality, maternal and fetal deaths due to complications from urinary tract 
infection still occur which should ideally be prevented. 
The prevalence of bacteriuria is the same in pregnant and non-pregnant women. Pregnant 
women are at the risk of recurrent bacteriuria. Without treatment, 30 to 40% of these 
pregnant women will develop symptomatic UTI. By treating asymptomatic bacteriuria in 
pregnant women, the risk of developing symptomatic UTI can be reduced by 70 to 80% 
(1). Asymptomatic bacteriuria and symptomatic urinary tract infection are associated with 
adverse maternal and fetal outcomes such as preterm birth, low birth weight infant, 
perinatal mortality, sepsis(1,2).  
The data from western population shows that the incidence of urinary tract infections is 
higher in pregnant women and it correlates with adverse maternal and fetal outcomes and 
it can be prevented by screening for asymptomatic bacteriuria. The Infectious Diseases 
Society of America (IDSA) and The American College of Obstetricians and 
Gynecologists (ACOG) guidelines advocate universal screening and treatment of 
asymptomatic bacteriuria among pregnant women. However, in resource poor and 
 18 
 
population dense region as in India, the data on maternal and fetal outcomes with 
symptomatic UTI is limited. Universal screening for asymptomatic bacteriuria is still not 
practiced. With increasing incidence of extended spectrum beta lactamase (ESBL) 
infections in the community, cost of treating a urinary tract infection is significantly higher 
than screening and treating for asymptomatic bacteriuria. 
The aim of this study is to assess adverse maternal and fetal outcomes that occur secondary 
to symptomatic UTI during pregnancy. The study also aims at looking at the risk factors 
for UTI, organisms causing UTI and antimicrobial susceptibility pattern of the organisms. 
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AIMS 
The aim of the study is to assess maternal outcomes and fetal outcomes that occur 
secondary to symptomatic urinary tract infection in pregnancy. 
PRIMARY OBJECTIVES 
To determine the maternal and fetal outcomes that result from symptomatic urinary tract 
infection in pregnancy. 
SECONDARY OBJECTIVES 
1. To determine the risk factors associated with urinary tract infection in pregnancy. 
2. To identify the organisms causing UTI. 
3. To identify the antimicrobial susceptibility pattern of the organisms. 
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REVIEW OF LITREATURE 
DEFINITION 
 
Urinary tract infection (UTI) is defined as symptoms of UTI in the form of increased 
frequency of micturition, urgency, lower abdominal pain, and dysuria, with or without 
fever. It is called complicated urinary tract infection if it occurs in individuals with 
structural or functional abnormalities of the genitourinary tract like in pregnant women(3). 
 
EPIDEMIOLOGY OF UTI IN PREGNANCY 
 
INCIDENCE 
The prevalence of asymptomatic bacteriuria among pregnant women is 1.9 to 9.5% (4) 
which is similar to that in non-pregnant women. However, pregnant women are at risk of 
recurrent bacteriuria. The incidence of UTI in pregnancy is higher than in general 
population in view of anatomical changes that occur during pregnancy. This can be lower 
urinary tract infection in the form of cystitis or upper urinary tract infection in the form of 
pyelonephritis. A study done in Wilford Hall USAF medical center which was published 
in 1981, looked at 9734 deliveries over a 6 year period and showed that the incidence of 
acute cystitis was 1.3% and 17% of these patients had recurrent urinary tract infection(5). 
Majority of these patients with acute cystitis had been screened for bacteriuria and had 
negative urine culture prior to onset of symptom. The most common organism was 
Escherichia coli and all the patients were treated as outpatients. The incidence of 
pyelonephritis was 0.5 to 2% as shown in the 18 year retrospective review of medical 
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records on 546,092 singleton pregnancies delivered in all Kaiser Permanente Southern 
California hospitals from 1993 through 2010(6). Most cases of pyelonephritis occur during 
second and third trimesters in this study. This study also showed that African or Hispanic 
women, younger age of pregnancy, lower education, smoking during pregnancy and 
delayed initiation of antenatal care was risk factors for urinary tract infection. Pregnant 
women with pyelonephritis in this study had higher number of spontaneous preterm births, 
acute kidney injury, septicemia and anemia as compared to the pregnant women without 
pyelonephritis. 
With respect to Indian epidemiology of urinary tract infection in pregnancy, several studies 
have been done. Study done in Jhalawar medical college, Rajasthan looked at pregnant 
women with or without symptoms of urinary tract infection. Pregnant women in different 
stages of pregnancy with or without symptoms of UTI who visited the antenatal clinic from 
November 2011 to March 2012 were screened for bacteriuria. This study showed 
significant growth in urine culture in 60 of the 250 samples screened which showed that 
24% of the pregnant women in the 5-month study period had significant bacteriuria. The 
pathogenic organisms isolated were Escherichia coli (E. coli) in 63% and Klebsiella 
pneumoniae in 8%(7). Among these 60 patients showing significant growth in urine 
culture, 45 (75%) had asymptomatic bacteriuria and 15 (25%) had symptomatic urinary 
tract infection(7). In another study done in Aligarh, pregnant women at different stages of 
pregnancy were screened for bacteriuria with urine culture. It looked at pregnant women 
with or without symptoms of urinary tract infection. Of all the urine cultures sent, 51.2% 
(4290/8379) showed significant growth. 74.8% (3210/4290) of these pregnant women were 
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asymptomatic and 25.2% (1080/4290) were symptomatic for UTI with 51.7% of the gram 
negative organisms being ESBL producing organisms showing high level antibiotic 
resistance to cephalosporins. This study showed the higher prevalence of asymptomatic 
bacteriuria among pregnant women when compared to symptomatic urinary tract 
infection(8). In these 2 studies, the incidence of asymptomatic bacteriuria was 18% 
(45/250) in the Jhalawar study and 38% (3210/8379) in the Aligarh study which was 
significantly higher than that shown in western population studies. Study done by Kant et 
al in 2017 in Faridabad, Haryana from March 2015 to May 2015, looked at 1253 pregnant 
women. This study showed the prevalence of asymptomatic bacteriuria of 1.1% and 
symptomatic bacteriuria was 2.2% with majority of the cases occurring in the third 
trimester(9). 
Table 1: Prevalence of symptomatic bacteriuria across Indian literature 
 
 
Study name Prevalence of bacteriuria Prevalence of Symptomatic 
bacteriuria 
1. Sabharwal et al (2012) (7) 24% 6% 
2. Rizvi et al (2011) (8) 51.2% 12.8% 
3. Kant S et al (2017)(9) 3.3% 2.2% 
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RISK FACTORS FOR URINARY TRACT INFECTION 
 
Several studies have been done to assess risk factors for urinary tract infection among 
pregnant women. Study done in Northwest Ethiopian hospital between January 2011 and 
April 2011 and published on July 2013, looked at 367 pregnant women of whom 37 had 
symptomatic urinary tract infection and 330 had asymptomatic urinary tract infection. This 
study showed that low family income, three or more sexual intercourses per week, past 
history of UTI and anemia as significant risk factors for UTI. Other risk factors which the 
study looked at were age of pregnant women, educational status, parity, gestational age, 
past history of catheterization, and genitourinary abnormality(10). These risk factors were 
not statistically significant for the development of symptomatic urinary tract infection as 
per this study.  
Diabetes in the form of gestational diabetes mellitus (GDM) is associated with increased 
risk of urinary tract infection(11). A study done by McMahon MJ et al in 1998, looked at 
824 women diagnosed with gestational diabetes mellitus in Canada between 1980 and 1993 
had increased incidence of urinary tract infection among pregnant women with GDM as 
compared to women without GDM (11).  
 
PATHOGENESIS OF URINARY TRACT INFECTION IN PREGNANCY 
 
Female urinary tract system undergoes anatomical and physiological changes during 
pregnancy(12). The changes that occur are summarized in the table 2 below. 
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Table 2: Urinary tract changes in pregnancy 
 
SITE CHANGE 
Kidneys - Increased renal length. 
- Increased glomerular filtration rate 
by 30 to 50%. 
Collecting system - Decreased peristalsis. 
Ureters - Decreased peristalsis. 
- Mechanical obstruction. 
Bladder - Displaced anteriorly and superiorly. 
- Smooth muscle relaxation. 
- Increased capacity. 
Data from Waltzer WC. The urinary tract in pregnancy. J Urol 1981(13) 
During pregnancy, there is hyperprogesteronemia that causes smooth muscle relaxation 
and decreased peristalsis in the ureters and collecting system. This along with the 
mechanical obstruction due to the gravid uterus causes mild hydroureteronephrosis which 
can be seen as early as 7th week of gestation (12).  
The prevalence of asymptomatic bacteriuria in pregnancy is almost the same as in non-
pregnant women. However, pregnant women are at increased risk of recurrent bacteriuria. 
Kass et al in 1960, has shown that asymptomatic bacteriuria during pregnancy predisposes 
to the development of pyelonephritis and asymptomatic bacteriuria if treated appropriately 
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can prevent development of symptomatic urinary tract infection. Kass et al showed that  
the presence of bacteriuria in an obstructed system caused an accelerated ascend of 
infection and pyelonephritis(13,14). In pregnancy, the gravid uterus can exert pressure on 
the bladder which can simulate an obstructed system. Pregnancy is also associated with 
immunomodulation as shown by Petersson et al in 1994 who looked at antibody response 
to E.coli antigen between pregnant and non-pregnant women. He looked at antibody 
activity and Interleukin 6 (IL-6) in serum and urine. 
 
Figure 1.Antibody activity in serum and urine at the time of diagnosis and two weeks later. 
Adapted from Suppressed antibody and interleukin-6 responses to acute pyelonephritis in 
pregnancy. Petersson et al. 1994.(15) 
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This study showed that pregnant women had lower levels of immunoglobulin G, 
immunoglobulin M and immunoglobulin E in serum and urine as compared to non-
pregnant women which was seen at the time of diagnosis of acute pyelonephritis and also 
after 2 weeks.  It also looked at change in antibody activity in serum and urine among non-
pregnant and pregnant women with acute pyelonephritis. It showed that the change in 
antibody activity was higher in the non-pregnant women as compared to the pregnant 
women and it was statistically significant. 
 
Figure 2. Urine and serum IL-6 activity in non-pregnant and pregnant women at the time 
of diagnosis of acute pyelonephritis. Adapted from Suppressed antibody and interleukin-6 
responses to acute pyelonephritis in pregnancy. Petersson et al. 1994.(15) 
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When the levels of IL-6 in urine and serum were compared between pregnant and non-
pregnant women, it was found that pregnant women had reduced levels of IL-6 to gram 
negative UTI which increases the risk of urinary tract infection in pregnant women (15). 
 
 
MICROBIOLOGY 
 
Urinary tract infection is most commonly caused by E.coli followed by Klebsiella in 
pregnant and non-pregnant women. Hill et al in 2005, studied pregnant women with 
pyelonephritis and found that the predominant uropathogen was E.coli with 83%, followed 
by Gram positive organisms like Group B Streptococcus which was 11.6%, followed by 
Klebsiella and Enterobacter which was 3.5% and Proteus which was 2.2% (16).  Various 
studies looking at microbiology of urinary tract infection in pregnancy are summarized 
below. 
TABLE 3: UROPATHOGENIC BACTERIA ISOLATED ACROSS LITERATURE 
 
Study Organism isolated 
Hill et al (2005)(16)  
N= 32,282 
440 patients developed 
antepartum pyelonephritis. 
- E.coli- 83% 
- Gram positive cocci (GPC)- 11.6% 
- Klebsiella- Enterobacter- 3.5% 
- Proteus- 2.2% 
Wing et al (2014) (6) - E.coli- 82.5% 
- Streptococcus species- 21.4% 
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N= 2894 cases of 
antepartum pyelonephritis. 
- Klebsiella pneumonia- 7.6% 
- Staphylococcus species- 6.5% 
- Proteus mirabilis- 4.9% 
- Enterococcus species- 5.7% 
Sabharwal et al (2012) (7) 
N= 250 pregnant women. 
- E.coli- 63.3% 
- Klebsiella- 8.3% 
- Pseudomonas- 1.7% 
- Proteus- 3.4% 
- Coagulase Negative Staphylococci (CONS)- 15% 
- Staphylococcus aureus- 8.3% 
Rizvi et al (2011)(8) 
N= 8379 pregnant women. 
- E. coli- 41.9% 
- Klebsiella pneumonia- 21.7% 
- Citrobacter species- 7.34% 
- Proteus mirabilis and Proteus vulgaris- 6.29% 
- Pseudomonas species- 3.4% 
- Staphylococcus saprophyticus and S.epidermidis- 6.4% 
- Staphylococcus aureus- 5.9% 
- Enterococcus faecalis- 3.4% 
- Streptococcus species- 3.4% 
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RISING PREVALENCE OF ANTIMICROBIAL RESISTANCE 
 
Several studies have looked at the rising prevalence of antimicrobial resistance among 
urinary tract infection. Schito et al studied 4264 healthy women with symptoms of 
uncomplicated lower urinary tract infection. 3081 patients had significant growth of more 
than 100,000 colony forming units/ml of urine in the culture (17). E.coli was the most 
common pathogen isolated with 76.7% followed by Staphylococcus saprophyticus which 
was 3.6%, Klebsiella pneumoniae which was 3.5%, and Proteus mirabilis which was 3.4%. 
Other Enterobacteriaceae such as Serratia, Enterobacter, Citrobacter, Morganella, Pantoea, 
Salmonella, and Hafnia were only 2.9%. Schito et al looked at antimicrobial resistance 
pattern in  strains of E.coli isolated from urinary tract infection (17). Ampicillin resistance 
was the most prevalent with 48.3 % of the E.coli strains being resistant to the same. This 
was followed by 29.4 % of the E.coli strains being resistant to Sulfamethoxazole/ 
Trimethoprim and 18.4% being resistant to Nalidixic acid (17). This study also looked at 
antimicrobial susceptibility pattern for Klebsiella, Proteus and Staphylococcus 
saprophyticus. 99% of the Klebsiella pneumoniae were resistant to Ampicillin followed by 
37.4 % resistant to Nitrofurantoin, 23.3% resistant to Sulfamethoxazole/ Trimethoprim and 
17.8 % being resistant to Nalidixic acid. The antimicrobial susceptibility pattern for Proteus 
showed 42.3% resistant to Nitrofurantoin, 37.5% resistant to Sulfamethoxazole/ 
Trimethoprim, 32.7 % resistant to Ampicillin, and 21.2% resistant to Nalidixic acid. 36.4 
% of the Staphylococcus saprophyticus were resistant to Ampicillin followed by 10.4 % 
resistance to Sulfamethoxazole/ Trimethoprim. 
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Another study done in Aligarh by Rizvi et al looked at 8379 urine samples collected during 
the five year study period (8). Of these, 4290 (51.2 %) showed significant growth in urine 
culture. The uropathogen most commonly isolated were E.coli in 41.9%, followed by 
Klebsiella pneumoniae, Citrobacter, Staphylococcal species and Enterococcus faecalis. 
The antimicrobial susceptibility pattern were studied (8). Among the Enterobacteriaceae, 
Ciprofloxacin resistance was 64.5%, Cefotaxime resistance was 51.2%, Nitrofurantoin 
resistance was 40%, Amikacin resistance was 19%, and Cefoperazone- sulbactum 
resistance was 7.8%. This showed high rates of resistance to Ciprofloxacin and 
Nitrofurantoin. Around 34 % of the Staphylococcus species were methicillin resistant. 
However, there was no resistance to Vancomycin among the Staphylococcal species.  
These studies showed that there is increase in urinary tract infections with ESBL producing 
uropathogen with significantly higher rate of resistance to beta-lactam group of antibiotics 
and Fluoroquinolones. Fluoroquinolones are contraindicated in pregnancy. This study also 
showed high rates of resistance to Nitrofurantoin (8). 
 
CLINICAL PRESENTATION 
 
Pregnant women can have bacteriuria which can be asymptomatic or symptomatic.  
ASYMPTOMATIC BACTERIURIA IN PREGNANCY 
IDSA 2005 guidelines, defined asymptomatic bacteriuria. It was defined as two 
consecutive voided urine specimens with isolation of the same bacterial isolate in ≥ 
100,000 colony forming units/ml in case of mid-stream voided urine sample or ≥ 100 
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colony forming units/ml in case of catheterized urine specimen (3). IDSA recommends 
screening of pregnant women for bacteriuria by urine culture at least once in early 
pregnancy which is before 16 weeks following which they showed be treated with 
appropriate antimicrobial therapy for 3 to 7 days in case of positive results. Periodic 
screening showed be done to look for recurrent bacteriuria in pregnancy and prophylactic 
antibiotics might be required (3). 
 
SYMPTOMATIC BACTERIURIA IN PREGNANCY 
Symptomatic bacteriuria can be further divided into the following types. 
- ACUTE CYSTITIS 
- ACUTE PYELONEPHRITIS 
Acute cystitis occurs secondary to infection and inflammation of the bladder. The patient 
presents with complains of dysuria, urinary urgency and frequency in the absence of fever 
and chills. As the pregnant women is symptomatic for the same and seeks treatment and 
the load of infection is mild, this is usually not associated with adverse outcomes. However, 
they are prone of recurrent bacteriuria (12,18). The incidence of cystitis during pregnancy 
is around 1 to 2% (5). 
Acute pyelonephritis occurs due to infection of the upper urinary tract and kidneys. These 
patients present with fever more than 100.4 F with flank pain, vomiting with nausea and 
costovertebral tenderness. The incidence of pyelonephritis among pregnancy is 0.5 to 2% 
(6,16). In view of severe infection, it is associated with adverse maternal and fetal 
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outcomes. Adverse maternal outcomes that occur include anemia, acute kidney injury, 
sepsis, acute respiratory distress syndrome. Adverse fetal outcomes that occur include 
preterm birth and low birth weight (12).  
 
SPECIMEN COLLECTION 
There are three techniques for collection of urine for culture 
1. Mid-stream voided sample 
2. Mid-stream clean catch voided sample.  
3. Urethral catheter sample 
4. Suprapubic aspiration. 
Proper specimen with as minimal contamination is required for appropriate diagnosis. 
Suprapubic aspiration is not feasible for pregnant women in view of the distended uterus 
and risk of trauma to the fetus. Urethral catheter sample in a sterile technique will help 
getting an accurate diagnosis. However, this technique is cumbersome and there is risk of 
introducing infection. Mid-stream sample is easy to collect but there is high risk of 
contamination. Mid-stream voided sample is collected by spreading the labia and collecting 
a midstream urine. Mid-stream clean catch voided sample differs from mid-stream voided 
sample as it is collected after local cleansing of the urethral meatus and surrounding 
mucosa and then collecting the second portion of urine after discarding the first portion. 
Study done by Schneeberger C et al in 2013, showed that the rates of contamination 
between midstream voided sample and midstream clean catch sample were similar(19).  
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CRITERIA FOR DIAGNOSIS OF URINARY TRACT INFECTION 
  
ASYMPTOMATIC BACTERIURIA 
IDSA 2005 guidelines defines asymptomatic bacteriuria as 
-“2 consecutive voided urine specimens with isolation of the same 
bacterial strain in quantitative counts of more than 105 colony forming units 
(CFU)/mL. “ 
 OR 
-“A single catheterized urine specimen with 1 bacterial species 
isolated in a quantitative count of 102 CFU/mL identifies 
bacteriuria in women.” (3) 
The original criterion for diagnosing asymptomatic bacteriuria which is more than 100,000 
CFU of bacteria/ml on two consecutive clean catch samples is cumbersome and not feasible 
in many situations due to financial constraints. The detection of more than 100,000 CFU 
of  bacterial/ ml in a single voided midstream urine is accepted as an adequate and more 
practical alternative, although there is only an 80% probability the woman has true 
bacteriuria. This probability increases to 95% if two or more consecutive cultures show 
significant growth (20,21).   
ACUTE CYSTITIS. 
Criteria for diagnosis of acute cystitis include 
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 Symptomatic urinary tract infection in the form of dysuria, increased 
frequency, urgency, lower abdominal pain with 
 Urine culture showing more than 100,000 CFU/ml of organism in a mid-
stream clean catch urine or more than 100 CFU/ml in case of catheterized 
urine sample. 
ACUTE PYELONEPHRITIS 
Criteria for diagnosis include 
 Symptomatic urinary tract infection with features of upper urinary tract 
infection in the form of fever with chills, lower back pain, renal angle 
tenderness with or without symptoms of lower urinary tract infection. 
 Urine culture showing more than 100,000 CFU/ml of organism in a mid-
stream clean catch urine or more than 100 CFU/ml in case of catheterized 
urine sample. 
DEFINITIONS 
 
Primigravida refers to a women who is pregnant for the first time (22). 
 
Multigravida refers to women who has been pregnant more than 2 times(23). 
 
Grand multigravida refers to a women who has had 5 or more deliveries (24). 
 
Elderly gravida refers to a women who becomes pregnant at an age of 35 years or more 
(25). 
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Teenage pregnancy is defined as pregnancy in a women of 19 years of age or less (26). 
 
Singleton pregnancy refers to single live intrauterine fetus (26)  
 
Multifetal pregnancy refers to 2 or more live intrauterine fetuses (26) 
 
Modified kuppuswamy scale, 2016 was used for calculating socioeconomic status of the 
participants (27). The basis of scoring and classification is shown in the table below. 
Table 3: Scoring for modified Kuppuswamy’s socio-economic status scale, revised for 
2016. 
 
Table 4: Kuppuswamy’s classification of socioeconomic status. 
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Anemia  
It is defined by Indian council of Medical Research, ICMR as per the following criteria. 
Table 5: ICMR definition of anemia 
 
DEGREE OF ANEMIA HEMOGLOBIN CUT OFF 
Mild  10 to 10.9 g/dl 
Moderate       7-9.9 
Severe           <7 
Very Severe   <4 
 
DEFINITION OF MATERNAL OUTCOMES 
 
Placental abruption 
Placental abruption is defined as the premature separation of the implanted placenta before 
the delivery of the fetus which is diagnosed based on clinical symptoms that include 
vaginal bleeding accompanied with severe abdominal pain, uterine tenderness, or tetanic 
contractions (28). 
 
Gestational Hypertension 
The diagnosis of gestational hypertension is made in women whose blood pressure reaches 
140/90 mm Hg or greater for the first time after mid pregnancy, but in whom proteinuria 
is not identified(29) 
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Pre-eclampsia 
Pre- eclampsia is defined as new onset hypertension after 20 weeks of gestation with the 
following criteria (30). 
Blood pressure  Greater than or equal to 140 mmHg systolic or greater than or equal 
to 90 mm Hg diastolic on 2 occasions at least 4 hours apart after 20 
weeks of gestation in a woman with a previously normal blood 
pressure. 
 Greater than or equal to 160 mm Hg systolic or greater than or equal 
to 110 mm Hg diastolic, hypertension can be confirmed within a 
short interval (minutes) to facilitate timely antihypertensive therapy. 
And 
Proteinuria  Greater than or equal to 300 mg per 24 hour urine collection (or this 
amount extrapolated from a timed collection) 
OR 
 Protein/ creatinine ratio greater than or equal to 0.3. 
 Dipstick reading of 1+ (used only if other quantitative methods not 
available) 
 
Or in the absence of proteinuria, new onset hypertension with the new onset of any of the 
following. 
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Thrombocytopenia Platelet count less than 100,000/ microliter. 
Renal 
insufficiency 
Serum creatinine concentrations greater than 1.1 mg/dl or a doubling of the 
serum creatinine concentrations in the absence of other renal disease 
Impaired renal 
function 
Elevated blood concentrations of liver transaminases to twice normal 
concentration 
Pulmonary edema  
Cerebral or visual 
symptoms 
 
 
Severe Pre- eclampsia 
Any of these findings makes the Pre- eclampsia severe- 
 Systolic blood pressure of 160 mm Hg or higher, or diastolic blood pressure of 110 
mm Hg or higher on two occasions at least 4 hours apart while the patient is on bed 
rest (unless antihypertensive therapy is initiated before this time). 
 Thrombocytopenia (platelet count less than 100,000/ microliter). 
 Impaired liver function as indicated by abnormally elevated blood concentrations of 
liver enzymes (to twice normal concentration), severe persistent right upper 
quadrant or epigastric pain unresponsive to medication and not accounted for by 
alternative diagnosis or both. 
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 Progressive renal insufficiency (serum creatinine concentration greater than 1.1 
mg/dl or a doubling of the serum creatinine concentration in the absence of other 
renal disease). 
 Pulmonary edema. 
 New onset cerebral or visual disturbances.  
 
Eclampsia 
Eclampsia is defined as the presence of new onset grand mal seizures in a woman with pre 
eclampsia. Eclampsia can occur before, during or after labor (30). 
 
Premature rupture of membranes (PROM) 
Premature rupture of the fetal membranes (PROM) is defined as the rupture of the amniotic 
membranes with release of the amniotic fluid more than 1 hour prior to the onset of labor. 
PROM may be subdivided into term PROM (i.e. PROM after 37 weeks of gestation) and 
preterm PROM (PPROM, i.e. PROM prior to 37 weeks of gestation) (31). 
 
Chorioamnionitis  
Chorioamnionitis or intraamniotic infection is an acute inflammation of the membranes 
and chorion of the placenta, typically due to ascending polymicrobial bacterial infection in 
the setting of membrane rupture. Clinical symptoms include fever, uterine fundal 
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tenderness, maternal tachycardia (>100/min), fetal tachycardia (>160/min) and purulent or 
foul amniotic fluid (32). 
 
Acute Pyelonephritis  
Acute pyelonephritis is an infection of the renal pelvis and kidney that usually results from 
ascent of a bacterial pathogen up the ureters from the bladder to the kidneys, is associated 
with lower urinary tract symptoms (e.g., urinary frequency, urgency, dysuria) accompanied 
by fever, nausea, vomiting, or flank pain with examination showing tenderness to palpation 
of the costovertebral angle (33). 
 
Operative Vaginal Delivery/ Instrumental Delivery 
Operative vaginal delivery are accomplished by applying direct traction on the fetal skull 
with forceps, or by applying traction to the fetal scalp by means of a vacuum extractor(34) 
. 
 
Cesarean Delivery 
A cesarean birth, often called a C-section, is the delivery of the baby through incisions in 
the mother’s abdomen and uterus (35). 
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DEFINITION OF FETAL OUTCOMES 
 
Intrauterine Growth Restriction (IUGR) 
IUGR is a fetus whose estimated weight is below the 10th percentile for its gestational age 
and whose abdominal circumference is below the 2.5th percentile for its gestational age 
(36).  
 
Preterm delivery 
Preterm is defined as babies born alive before 37 weeks of pregnancy are completed. There 
are sub-categories of preterm birth, based on gestational age: 
 Extremely preterm (<28 weeks) 
 Very preterm (28 to <32 weeks) 
 Moderate to late preterm (32 to <37 weeks) (37). 
 
Low birth weight  
Low birth weight has been defined by the World Health Organization (WHO) as weight at 
birth of less than 2,500 grams (5.5 pounds) (38). 
Very low birth weight is less than 1,500 g (up to and including 1,499 g) (38).  
Extremely low birth weight is less than 1,000 g (up to and including 999 g) (38).  
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Still birth 
 
Stillbirth is a fetal death that occurs during pregnancy at 22 weeks or greater gestation or 
at weight greater than or equal to500g (39).  
 
Birth Asphyxia  
AAP/ACOG criteria (40).  
1. Arterial cord pH < 7.0  
2. Apgar score of 3 or less for greater than 5 minutes  
3. Evidence of altered neurological status (seizures, obtundation, etc.)  
4. Multisystem organ injury or failure 
 
RATIONALE FOR TREATMENT OF URINARY TRACT INFECTION IN 
PREGNANCY 
 
As mentioned earlier, the incidence of bacteriuria is similar between pregnant and non-
pregnant women. However, pregnant women are at higher risk for symptomatic urinary 
tract infection and recurrent bacteriuria (1). Several studies have shown that treatment of 
asymptomatic bacteriuria reduces the incidence of symptomatic urinary tract infection and 
improves outcome. This was shown in a meta-analysis which was published in Cochrane 
Database Systematic review in 2015. It looked at randomized trials which involved 
pregnant women who were diagnosed with asymptomatic bacteriuria on antenatal checkup 
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and compared antibiotic treatment versus no treatment or placebo in them. There was a 
total of 14 studies which involved 2000 women which showed that antibiotic therapy 
reduced the incidence of pyelonephritis (average risk ratio (RR) 0.23, 95% confidence 
interval (CI) 0.13 to 0.41), reduced the incidence of low birth weight infants (average RR 
0.64, 95% CI 0.45 to 0.93) and preterm birth (RR 0.27, 95% CI 0.11 to 0.62), and there 
was reduction in persistent bacteriuria (average RR 0.30, 95% CI 0.18 to 0.53). This meta-
analysis showed that antibiotic treatment in case of asymptomatic bacteriuria was 
beneficial in reducing the risk of pyelonephritis. On the other hand, the quality of evidence 
was poor and the conclusions have to be interpreted with caution(1).  
Study done in Soroka University Medical Center, Israel, looked at 199,093 singleton 
deliveries which occurred in this hospital between 1988 and 2007. Pregnant women with 
asymptomatic bacteriuria were excluded. The study compared pregnant women with 
culture proven symptomatic urinary tract infection with pregnant women without urinary 
tract infection. Out of the 199,093 deliveries, 4742 which is 2.3% had symptomatic UTI. 
Pregnant women with symptomatic UTI had a higher incidence of preterm delivery, lower 
birth weight, recurrent abortions, intrauterine growth restrictions, premature rupture of 
membranes, chorioamnionitis, and caesarean delivery. Renal abnormalities such as 
pyelonephritis, hydroureteronephrosis, renal nephrolithiasis and renal abscess were more 
common in pregnant women with UTI. Assessment of fetal and neonatal outcome also 
revealed that pregnant women with UTI had infants with lower APGAR score at 1 min but 
similar APGAR score at 5 min and perinatal mortality in the two arms were also 
comparable (41). All these studies reveal that treatment of asymptomatic bacteriuria and 
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symptomatic urinary tract infection during pregnancy results in better maternal and fetal 
outcomes. 
 
MANAGEMENT OF URINARY TRACT INFECTIONS DURING PREGNANCY 
 
Pregnant women with symptoms of urinary tract infection requires treatment in view of the 
adverse outcomes associated with it as mentioned above. They can be treated with oral or 
IV antibiotics based on the severity of symptoms (42). In case of mild symptoms, oral 
antibiotics usually suffice. In case of signs of sepsis or systemic symptoms, the pregnant 
women will require admission for intravenous antibiotics. In such patients, ultrasound 
abdomen is required to look for renal abscess and hydroureteronephrosis. Antimicrobial 
susceptibility reports need to be followed by and antibiotics appropriately tailored for the 
same.
 
Figure 3. Suggested approach to the management of urinary tract infection (UTI) in 
pregnancy in women who have no signs of fetal compromise. Adapted from A likely urinary 
tract infection in a pregnant woman. Johnston et al. BMJ 2017.(42) 
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Based on the pathogenic organisms and trimester of pregnancies, a variety of antimicrobial 
agents are available for treatment of urinary tract infection. Treatment is challenging in 
pregnant women in view of teratogenicity of certain antimicrobial agents on the fetus and 
in view of the rising prevalence of antimicrobial resistance among the pathogenic 
organisms. The figure below looks at commonly used antimicrobial agents and fetal 
toxicity. 
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Figure 4. Antimicrobials in pregnancy. Adapted from Urinary Tract Infection and 
Bacteriuria in Pregnancy. Glaser et al. Urology clinics of North America. 2015(12). 
This shows that a wide variety of antimicrobial agents are available for the treatment of 
UTI in pregnancy but the options are limited when it comes to infections with resistant 
organisms as data for newer antibiotics are limited.  
MATERIALS &METHODS 
SETTING 
This study was carried out in Christian Medical College (CMC), Vellore, which is a 2700-
bedded tertiary care teaching hospital in South India. The hospital serves the population of 
Tamil Nadu and the neighboring state of Andhra Pradesh, besides being a referral center 
for patients from other parts of the country and the Indian subcontinent. 
Patients were recruited from June 2017 to June 2018 after obtaining approval from the 
institutional research board (IRB No. 10627). 
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STUDY DESIGN 
This was a cross-sectional study. Pregnant women who delivered in CMC and CMC allied 
hospitals, with at least 3 visits to the OPD prior to delivery were included. 
PARTICIPANTS 
Pregnant women with symptomatic urinary tract infection with culture confirmed infection 
were recruited as cases. Controls were pregnant women without symptomatic urinary tract 
infection who delivered in CMC or CMC allied hospitals. 
 
BASELINE ASSESSMENT FOR THE PREGNANT WOMEN: 
 
All pregnant women who visit CMC, undergo regular antenatal check up with the 
following tests 
Clinical parameters 
a. Heart rate of mother 
b. Blood pressure of mother 
c. Size of uterus  
d. Fetal movements 
e. Fetal heart sound 
Laboratory parameters 
a. Haemoglobin 
b. Urine routine 
c. Urine culture 
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d. OGTT 
e. VDRL 
f. Fetal ultrasound 
g. Urine albumin. 
INCLUSION CRITERIA: 
Inclusion criteria for this study- 
 Pregnant women more than 18 years of age. 
 Should have received antenatal care from CMC (3 visits before 
labour). 
 Should have delivered in CMC labour room. 
 Should give informed consent. 
EXCLUSION CRITERIA: 
Exclusion criteria for prospective arm of this study. 
 Participants who do not give informed consent. 
 Participants who are not booked for antenatal care in CMC. 
STUDY PROCEDURE: 
In this cross sectional study, pregnant women who deliver in CMC, will be assessed for 
history of symptomatic UTI with positive urine culture and will be compared with pregnant 
women without UTI to assess the adverse maternal and fetal outcomes that occur secondary 
to UTI. The participants were recruited from July 2017 to August 2018 from CMC labour 
room after taking informed consent. They were then interviewed during their stay in 
hospital for risk factors that predispose to UTI. The fetal and maternal outcomes as pre-
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specified were collected from the patients chart and the data entry forms were filled. The 
data from Clinical microbiology on urine and blood culture characteristics were collected 
for assessing the antimicrobial susceptibility pattern.  
PATIENT RECRUITMENT AND ASSESSMENT: 
Pregnant women who delivered in CMC labor room were recruited. Cases were pregnant 
women who delivered in CMC with past history of urinary tract infection during the 
antenatal period with urine culture showing more than 100,000 CFU/ml of pathogenic 
organisms in mid-stream clean catch urine specimen or more than 100 CFU/ml in catheter 
sample.  
Pregnant women without symptomatic urinary tract infection who delivered in CMC labor 
room was recruited as controls. 
The participants were recruited after delivery in CMC when they were visited and informed 
consent was taken following which questionnaire was administered to them. 
OUTCOMES ASSESSED 
PRIMARY OUTCOME: 
To determine the maternal and foetal outcomes secondary to symptomatic urinary tract 
infection in pregnancy. 
SECONDARY OUTCOMES:  
 
 To determine the risk factors associated with Urinary tract infection in pregnancy. 
 To identify the organisms causing UTI. 
 To identify the antimicrobial susceptibility pattern of the organisms. 
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SAMPLE SIZE 
 
The required sample size to find the maternal and neonatal outcomes due to UTI during 
pregnancy was found to be about 200 UTI and 400 non UTI subjects with 80% power and 
5% level of significance with an anticipated proportion of 8% preterm delivery among UTI 
women which was taken from the article written by Efrat Mazor-dray et al which was 
published in February 2009 (41). 
Formula:  
 
Reference for above formula: Sahai H, Kurshid A.  Formulae and tables for the 
determination of sample size and power in clinical trials for testing differences in 
proportions for the two sample design: a review. Statistics in Medicine, 1996; 15: 1-21. 
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Epidemiology Methods - Unmatched Cross sectional Studies - Equal Allocation 
- Hypothesis testing of the odds ratio 
Probability of exposure in control group 0.08  
Anticipated odds ratio 2  
Probability of exposure in case group 0.1481  
Power (1- beta) % 80  
Alpha error (%) 5  
1 or 2 sided 2  
Required sample size in each of the case && control groups 341  
 
Hence, the calculated sample size was 341 in each arm. 
STATISTICAL ANALYSIS: 
 
Data entry was done using EPIDATA Software 3.1. Statistical analysis was done SPSS 
version 24. The quantitative variables were birth weight of the baby, gestational age of the 
mother, age of the mother. These variables were expressed in terms of mean with standard 
deviation (SD) or median with Interquartile range (IQR) based on the distribution of the 
variables in each group. The comparison of the quantitative variables were done using 
independent t-test or Wilcoxon rank sum test depending on the distribution.  
The categorical variables like preterm delivery, IUGR, pre-eclampsia, etc., were expressed 
as frequencies across the UTI and non UTI subjects. Comparison of these variables across 
the groups were done using Fisher’s Exact test.  
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All significant variables in the above analysis were analysed using Logistic regression and 
P value < 0.05 was considered as statistical significance. Hosmer Lemeshow statistic were 
reported to assess the goodness of fit of the final model.  
INSTITUTIONAL REVIEW BOARD AND ETHICS COMMITTEE CLEARANCE: 
 
The study design and methods were approved by the institutional review board (blue) and 
ethics committee of Christian Medical College, Vellore (IRB Min. No. 10627, dated 
04.04.2017). A copy of the IRB approval statement can be found in Annexure. 
 
FUNDING OF THE STUDY: 
 
This study was funded by fluid research grant number 22Z404 of Christian Medical 
College, Vellore. 
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STUDY FLOW DIAGRAM: 
 
FIGURE 11: Study flow diagram 
RESULTS 
 
This cross sectional study was done from July 2017 through August 2018. During this 
period 415 patients were recruited. Five patients were excluded, as they refused to 
provide consent. Thus, four hundred and ten patients (N= 410) patients were included in 
the final analysis (Figure 12). 
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FIGURE 12: STROBE Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Participants screened 
N = 415  
 
Patient included for analysis 
N = 410 
 
Refused consent 
N= 5 
10,530 deliveries in CMC between July 2017 and August 2018 and 
were eligible for recruitment 
 
Cases 
N= 202 
Controls 
N = 208 
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BASELINE CHARACTERISTICS OF CASES AND CONTROLS 
410 patients were recruited for the study. Of the 410 patients, 202 were cases and 208 
were controls. Mean age of the study population was 26.44, with median of 26 (IQR: 18 
– 45) years. It composed mainly of women from Tamil Nadu and Andhra Pradesh as only 
women for were booked for the antenatal care in this institution were included.  
Table 6: Baseline characteristics of the cases and controls (N = 410) 
 
Sex  
Female 
Cases 
100% 
Controls 
100% 
Mean Age 
(Mean +/- SD) 
 
26.44 
 
28.65 +/- 4.20 
 
26.05 +/- 4.20 
Parity Primigravida 
216 (52.6%) 
Multigravida 
187 (45.6%) 
Grand multigravida 
7 (1.7%) 
Cases- 116 (57.4%) 
 
Cases- 81 (40.1%) 
 
Cases- 5 (2.5%) 
 
Controls- 100 (48.1%) 
 
Controls- 106 (51%) 
 
Controls- 2 (1%) 
Singleton pregnancy 
Multifetal pregnancy 
401 (97.8%) 
9 (2.2%) 
Cases-194 (96%) 
Cases- 8 (4%) 
Controls- 207 (99.5%) 
Control- 1 (0.5%) 
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Fertility treatment 
Yes 
No 
 
22 (5.4%) 
388 (94.6%) 
 
Cases- 13 (6.4%) 
Cases- 189 (93.6%) 
 
Controls- 9 (4.3%) 
Controls- 199 (95.7%) 
Number of abortions 
1 
2 
3 
 
55 (13.4%) 
20 (4.8%) 
4 (1%) 
 
Cases- 26 (12.9%) 
Cases- 13 (6.4%) 
Cases- 2 (1%) 
 
Control- 29 (13.9%) 
Controls- 7 (3.4%) 
Controls- 2 (1%) 
Number of recurrent 
abortions 
Total= 24 (5%) 
 
Cases- 15 
 
Controls- 9 
Educational status 
Primary school 
Middle school 
High school 
Intermediate or 
post high school 
Graduate or post 
graduate 
 
1 (0.2%) 
57 (13.9%) 
129 (31.5%) 
73 (17.8%) 
 
147 (35.9%) 
 
 
Case- 0 
Case- 36 (17.8%) 
Case- 64 (31.7%) 
Case- 56 (27.7%) 
 
Case- 46 (22.8%) 
 
 
Control- 1 (0.5%) 
Control- 21 (10.1%) 
Control- 65 (31.3%) 
Control- 17 (8.2%) 
 
Control- 101 (48.6%) 
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Professional or 
honors 
3 (0.7%) 
 
Case- 0 
 
Control- 3 (1.4%) 
Occupation 
Unemployed 
Unskilled 
Semiskilled 
Skilled 
Clerical/ Farmer/ 
Shop owner 
Semi professional 
Professional 
 
6 (1.4%) 
34 (8.2%) 
11 (3.7%) 
27 (6.6%) 
155 (37.8%) 
 
94 (22.9%) 
83 (20.2%) 
 
Case- 6 (2.9%) 
Case- 7 (3.5%) 
Case- 2 (0.99%) 
Case- 16 (7.9%) 
Case- 93 (46%) 
 
Case-47 (23.3%) 
Case- 31 (15.3%) 
 
Control- 0 
Control- 27 (12.98%) 
Control- 9 (4.32%) 
Control- 11 (5.3%) 
Control- 62 (29.8%) 
 
Control- 47 (22.6%) 
Control-52 (25%) 
Family monthly 
income (Rs) 
0 – 2091 
2092 – 6213 
6214 – 10356 
10357 – 15535 
15536- 20714 
 
 
1 (0.2%) 
5 (1.2 %) 
71 (17.3%) 
160 (39%) 
 
 
Case- 1 (0.5%) 
Case- 5 (2.5%) 
Case- 29 (14.4%) 
Case- 72 (35.64%) 
 
 
Control- 0 
Control- 0 
Control- 42 (20.2%) 
Control- 89 (42.8%) 
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20715- 41429 
> 41430 
102 (24.9%) 
54 (13.2%) 
17 (4.1%) 
Case- 57 (28.2%) 
Case- 23 (11.4%) 
Case- 16 (7.9%) 
Control- 45 (21.6%) 
Control- 31 (14.9%) 
Control- 1 (0.5%) 
Modified 
kuppuswamy SES 
score 
Upper lower 
Lower middle 
Upper middle 
Upper 
 
 
 
55 (13.4%) 
174 (42.4%) 
135 (2.9%) 
46 (11.2%) 
 
 
 
Case- 20 (9.9%) 
Case- 100 (49.5%) 
Case- 62 (30.7%) 
Case- 20 (9.9%) 
 
 
 
Control- 35 (16.8%) 
Control- 74 (35.6%) 
Control- 73 (35.1%) 
Control- 26 (12.5%) 
Genitourinary 
abnormality 
 
15 (3.6%) 
 
Cases- 9 (4.5%) 
 
Controls- 6 (2.9%) 
Past history of 
catheterization 
 
34 (8.3%) 
 
Cases- 24 (11.9%) 
 
Control- 10 (4.8%) 
Past history of UTI 4 (0.97%) Cases- 4 (2%) Controls- 0 
Gestational 
diabetes mellitus 
 
102 (24.9%) 
 
Cases- 49 (24.3%) 
 
Controls- 53 (25.5%) 
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Pregestational 
diabetes mellitus 
 
6 (1.5%) 
 
Cases- 5 (2.5%) 
 
Controls- 1 (0.5%) 
Chronic 
hypertension 
8 (2%) Cases- 3 (1.5%) 
 
Controls- 5 (2.4%) 
 
PARITY OF PREGNANCY 
 
53.2% of the women were primigravida, 46.3% of the women were multigravida and 0.5% 
were grand multipara.  Among the cases 57.4 % were primigravida and 40.1 % were 
multigravida.  Among the controls, 48.1 % were primigravida and 51 % were multigravida. 
 
Figure 5: Distribution of parity among cases and controls 
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SINGLETON VERSUS MULTIFETAL PREGNANCY 
 
Among the participants studied, 97.8% had singleton pregnancy and 2.2% had multifetal 
pregnancy which has been represented in the pie chart. 
 
Figure 6: Singleton versus multifetal pregnancy. 
 
 
EDUCATIONAL STATUS 
 
Majority of the participants have received some form of education with 13.9 % completing 
middle school education, 31.5 % completing high school education, 17.8% completing 
Intermediate or post high school diploma, and 35.9% completing graduate courses. 
401 (97.8%)
9 (2.2%)
SINGLETON VERSUS MULTIFETAL PREGNANCY
SINGLETON MULTIFETAL PREGNANCY
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Figure 7: Educational status 
 
 
 
OCCUPATIONAL STATUS 
 
 
Majority of the participants have employed with 37.8 % working in a clerical/ farming/ 
shop owner profession, 22.9 % employed in semiprofessional job and 20.2% employed in 
a professional job. 1.4% were unemployed and 8.2% had an unskilled profession. 
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Figure 8: Occupation 
 
 
MONTHLY INCOME 
 
The distribution of income has been shown in the graph below. 
 
 
Figure 9: Monthly income 
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MODIFIED KUPPUSWAMY SES SCORE 
 
The pie chart below demonstrates the modified kuppuswamy SES score. 42.4% belonged 
to the lower middle category. 13.4 % belonged to the upper lower category. 11.2% 
belonged to the upper category and 2.9% belonged to the upper middle category.  
 
Figure 10: MODIFIED KUPPUSWAMY SES SCORE 
 
RISK FACTORS ASSOCIATED WITH URINARY TRACT INFECTION 
 
Elderly gravida versus urinary tract infection 
 
Elderly gravida is defined as pregnancy at 35 years of age or above. Age more than or equal 
to 35 years is associated with adverse outcomes (43). . When we looked at the same with 
respect to risk of urinary tract infection in elderly women. There was no statistically 
significant difference between the two groups. 
13.40%
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Table 7: Elderly gravida versus urinary tract infection. 
 
ELDERLY 
GRAVIDA 
Cases Controls OR 95 % CI P value 
Age≥ 35 years 5 (2.5%) 9 (4.3%) 0.561 0.185- 1.704 0.224 
Age < 35 years 197 (97.5%) 199 (95.7%) 
 
 
Teenage pregnancy versus urinary tract infection 
 
Similarly, teenage pregnancy which is defined as pregnancy at age of 19 years or less than 
19 years is associated with adverse maternal and fetal outcomes (44). When we looked at 
the same with respect to risk of urinary tract infection. There was no statistically significant 
difference between the two groups. 
Table 8: Teenage pregnancy versus urinary tract infection 
 
 
TEENAGE 
PREGNANCY 
Cases Controls OR 95% CI P value 
Age ≤ 19 y 3 (1.5%) 7 (3.4%) 0.433 0.110- 
1.698 
0.181 
Age > 19 y 199 (98.5%) 201 (96.6%) 
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Primigravida versus multigravida and risk of urinary tract infection 
 
This table shows that primigravida patients had increased risk of urinary tract infection 
with OR of 1.458 and P value which was statistically significant.  
Table 9: Parity versus urinary tract infection 
 
PARITY Cases CONTROLS OR 95% CI P VALUE 
PRIMIGRAVIDA 117 (57.92%) 101 (48.6%) 1.458 0.987 – 
2.153 
0.036 
MULTIGRAVIDA 85 (42.1%) 107 (51.4%) 
 
 
Singleton versus Multifetal gestation versus UTI 
 
Multifetal pregnancy can be associated with more adverse maternal and fetal outcomes and 
increased risk of urinary tract infection. The table below showed the increased risk of 
urinary tract infection in multifetal pregnancy with odds ratio of 8.53 ( 95% CI 1.05-68.8) 
which was statistically significant  (p<0.05) (45).  
Table 10: Multifetal pregnancy versus urinary tract infection. 
 
 Cases Controls OR 95% CI P value 
Multifetal 8 (4%) 1 (0.5%) 8.53 1.05 to 68.88 0.044 
Singleton 194 (96%) 207 (99l5%) 
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Trimester at which UTI occurred 
 
This study showed that urinary tract infection occurred most commonly in the third 
trimester followed by second trimester. 
Table 11: Incidence of urinary tract infection in each trimester 
 
TRIMESTER FREQUENCY PERCENTAGE 
FIRST TRIMESTER 22 10.9 % 
SECOND TRIMESTER 49 24.3 % 
THIRD TRIMESTER 131 64.9 % 
 
 
Figure 11: Incidence of urinary tract infection in each trimester 
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Fertility treatment versus UTI 
 
In this study, 5% of the participants conceived following fertility treatment. The risk of 
urinary tract infection following assisted reproduction was looked at. There was no 
statistically significant risk of urinary tract infection following conception after fertility 
treatment. 
Table 12: Fertility treatment and risk of urinary tract infection 
 
FERTILITY 
TREATMENT 
CASES  (N) CONTROL 
(N) 
OR 95% CI P VALUE 
YES 13 (6.4%) 9 (4.32%) 1.521 0.635 - 
3.641 
0.897 
NO 189 (93.6%) 199 (95.7%) 
TOTAL 202 208 
 
 
Abortion versus case and control 
 
 
We looked at abortion as well as recurrent abortion as risk factor for urinary tract 
infection. There was no statistically significant association between abortion and risk of 
urinary tract infection. 
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Table 13: Abortion and urinary tract infection 
 
ABORTION CASES CONTROLS OR 95% CI P VALUE 
YES 41 (20.3%) 38 (18.3%) 1.139 0.697– 1.862 0.346 
NO 161 (79.7%) 170 (81.7%) 
 
Table 14: Recurrent abortion and urinary tract infection. 
 
RECURRENT 
ABORTION 
CASES CONTROLS OR 95% CI P VALUE 
YES 15 (36.6%) 9 (23.7%) 1.859 0.697- 
4.960 
0.158 
NO 26 (63.4%) 29 (76.3%) 
 
 
Education versus case and control 
 
The impact of education on risk of urinary tract infection was looked at. Participants were 
divided into 2 groups. Low education group comprised of participants who have education 
up to middle school certificate. High education group refers to participants who have 
completed high school certificate or beyond. Low level of maternal education is associated 
with adverse maternal and fetal outcomes and increased risk of urinary tract infection as 
shown by OR  of 1.83 (95%CI 1.03 – 3.24, p<0.05) 
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Table 15: Maternal education and urinary tract infection 
 
EDUCATION CASES CONTROLS OR 95% CI P VALUE 
Low education 36 (17.8%) 22 (10.6%) 1.834 1.03 – 3.24 0.025 
High education 166 (82.2%) 186 (89.4%) 
 
 
Kuppuswamy SES versus urinary tract infection. 
 
Participants were categorized as low SES which included participants falling into upper 
lower, lower middle and upper middle. High SES included participants who belonged to 
upper SES status as per Kuppuswamy score. There was no statistically significant 
association between SES score and risk of urinary tract infection.  
Table 16: Kuppuswamy SES score and urinary tract infection 
 
SES CASES CONTROL OR 95% CI P VALUE 
LOW SES 182 (90.1%) 182 (87.5%) 0.404 0.70- 2.41 0.173 
HIGH SES 20 (9.9%)  26 (12.5%) 
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Genitourinary abnormality versus case and control 
 
There were a total of 15 patients with genitourinary abnormality. These various 
genitourinary abnormalities seen are summarized in the table below. The most common 
was renal calculi with hydroureteronephrosis, followed by fibroid uterus, bicornuate 
uterus, unicornuate uterus and vaginal stenosis. 9 of these had urinary tract infections and 
6 did not have urinary tract infection. There was no statistically significant association 
between genitourinary abnormality and risk of urinary tract infection. 
 
Table 17: Genitourinary abnormalities 
Genitourinary abnormality Number 
Renal calculi with Hydroureteronephrosis 4 
Fibroid uterus 3 
Bicornuate uterus 2 
Unicornuate uterus 2 
Septate uterus 1 
Vaginal septum 1 
Vaginal stenosis 2 
Total 15 
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Table 18: Genitourinary abnormality and urinary tract infection. 
 
Genitourinary 
abnormality 
Cases Control OR 95% CI P value 
Yes 9 (4.5%) 6 (2.9%) 1.753 0.625- 
4.918 
0.205 
No 193 (95.5%) 202 (97.1%) 
 
 
Past history of catheterization 
 
A total of 34 patients had past history of urinary tract infection. Of these, 24 were cases 
and 10 were controls. Past history of catheterization were associated with increased risk 
of urinary tract infection with an odds ratio of 2.670 (95% CI 1.24- 5.737, p= 0.007). 
Table 19: Past history of catheterization and urinary tract infection 
 
Past history of 
catheterization 
CASES CONTROLS OR 95% CI P 
VALUE 
YES 24 (11.9%) 10 (4.8%) 2.670 1.24- 
5.737 
0.007 
NO 178 (88.1%) 198 (95.2%) 
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Past history of UTI 
 
There were 4 patients with past history of urinary tract infection. All four patients 
developed symptomatic urinary tract infection during the antenatal period. This was 
statistically significant (p= 0.058)  
Table 20: Past history of UTI 
 
PAST HISTORY OF UTI CASES CONTROL P VALUE 
YES 4 0 0.058 
NO 198 208 
 
 
Gestational diabetes mellitus and urinary tract infection 
 
There were 49 patients with GDM in the cases and 53 patients in the controls. There was 
no statistically significant risk of urinary tract infection in pregnant women with GDM. 
Table 21: GDM and UTI 
 
GESTATIONAL 
DM 
CASES CONTROLS OR 95% CI P VALUE 
YES 49 (24.3%) 53 (25.5%) 0.937 0.598 – 
1.466 
0.432 
NO 153 
(75.7%) 
155 (74.5%) 
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Pregestational diabetes mellitus and urinary tract infection 
 
The number of participants with pregestational diabetes mellitus was 6 which was 1.5% of 
the participants studied. There was no statistically significant increase in urinary tract 
infection among pregnant women with pregestational DM. 
Table 22: Pregestational DM and UTI 
 
PREGESTATIONAL 
DM 
CASES CONTROLS OR 95% CI P VALUE 
PRESENT 5 (2.5%) 1 (0.5%) 5.254 0.608- 
45.369 
0.101 
ABSENT 197 (97.5%) 207 (99.5%) 
 
Chronic hypertension and urinary tract infections 
 
The incidence of chronic hypertension between cases and control were looked at. There 
were only 3 cases and 5 controls with chronic hypertension. There was no statistically 
significant increase in urinary tract infection risk among cases and controls with chronic 
hypertension. 
Table 23: Chronic hypertension and UTI 
 
HTN CASES CONTROL OR 95% CI P VALUE 
HTN YES 3 (1.5%) 5 (2.4%) 0.612 0.144- 2.595 0.378 
HTN NO 199 (98.5%) 203 (97.6%) 
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Anemia as a risk factor for UTI. 
 
Anemia during pregnancy is associated with adverse outcomes.  Anemia during pregnancy 
is classified by ICMR as mild, moderate and severe. Mild anemia is 10 to 11 g/dl. Moderate 
anemia is 7 to 10g/dl and severe anemia is  4 to 7 mg/dl (46). This study done showed that 
anemia is associated with urinary tract infection with Odds ratio of 1.48 which was 
statistically significant (p= 0.05). 
Table 24: Anemia and UTI 
 
Hb < 11g/dl CASES CONTROLS OR 95% CI P VALUE 
YES 65 (32.5%) 51 (24.6%) 1.484 0.973 – 
2.263 
0.05 
NO 135 (67.5%) 156 (75.4%) 
 
SUMMARY OF RISK FACTORS ASSOCIATED WITH URINARY TRACT 
INFECTION 
 
Risk factor Cases 
N= 202 
Controls 
N= 208 
Or 95% ci P value 
Elderly gravida 
(Age >/= 35 yrs) 
5 (2.5%) 9 (4.3%) 0.561 0.185- 1.704 0.224 
Teenage pregnancy 
( Age </= 19 yrs) 
3 (1.5%) 7 (3.4%) 0.433 0.110- 1.698 0.181 
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Primigravida 117 (57.92%) 101 (48.6%) 1.458 0.987 – 2.153 0.036 
Multifetal pregnancy 8 (4%) 1 (0.5%) 8.53 1.05 to 68.88 0.044 
Fertility treatment 13 (6.4%) 9 (4.3%) 1.521 0.635 - 3.641 0.897 
Abortion 41 (20.3%) 38 (18.3%) 1.139 0.697– 1.862 0.346 
Recurrent abortions 15 (36.6%) 9 (23.7%) 1.859 0.697- 4.960 0.158 
Low Maternal 
education 
36 (17.8%) 22 (10.6%) 1.834 1.037 – 3.243 0.025 
Low Kuppuswamy 
SES scale 
182 (90.1%) 182 (87.5%) 0.404 0.70- 2.41 0.173 
Genitourinary 
abnormality 
9 (4.5%) 6 (2.9%) 1.753 0.625- 4.918 0.205 
Past history of 
Catheterization 
24 (11.9%) 10 (4.8%) 2.670 1.24- 5.737 0.007 
Gestational DM 49 (24.3%) 53 (25.5%) 0.937 0.598 – 1.466 0.432 
Pregestational DM 5 (2.5%) 1 (0.5%) 5.254 0.608- 45.369 0.101 
Chronic hypertension 3 (1.5%) 5 (2.4%) 0.612  0.144- 2.595 0.378 
Anemia 
Hb < 11g/dl 
65 (32.5%) 51 (24.6%) 1.484 0.973 – 2.263 0.05 
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MATERNAL OUTCOMES 
 
Urinary tract infection can be associated with adverse maternal outcomes such as 
premature delivery, low birth weight infants, placental abruption, pre-eclampsia, premature 
rupture of membranes, preterm premature rupture of membranes, chorioamnionitis, and 
renal complications like pyelonephritis, LSCS (41). 
 
Placental abruption 
  
Out of the 410, patients studied, placental abruption occurred in 2.5% of pregnant women 
with UTI and 1.9 % of women without UTI. The odds ratio was 1.29 (95% CI: 0.343-
4.891). The difference was not statistically significant (p=0.482). 
 
Gestational Hypertension and mild pre-eclampsia 
 
Out of the 410 patient’s studied, Gestational hypertension and mild pre –eclampsia 
occurred in 6.4% women with UTI versus 4.3% women without UTI. The odds ratio was 
1.521 (95% CI: 0.635- 3.641). The difference was not statistically significant (p=0.234). 
 
Severe preeclampsia to eclampsia 
 
Out of the 410 patients studied, severe pre-eclampsia to eclampsia occurred in 5.4% women 
with UTI versus 4.8% women without UTI. The odds ratio was 1.076 (95% CI: 0.473- 
2.747). The difference was not statistically significant (p=0.472). 
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Premature rupture of membranes 
 
Out of the 410 patients studied, premature rupture of membranes occurred in 2.0% women 
with UTI versus 3.8 % women without UTI. The odds ratio was 0.505 (95% CI: 0.150- 
1.704). The difference was not statistically significant (p=0.205). 
  
Preterm premature rupture of membranes 
 
Out of the 410 patients studied, preterm premature rupture of membranes occurred in 17.3 
% women with UTI versus 7.2 % women without UTI. The odds ratio was 2.697 (95% CI: 
1.423- 5.111). The difference was statistically significant (p=0.001). 
Table 25: PPROM and UTI 
 
PPROM CASES (N) CONTROLS (N) OR 95% CI P VALUE 
YES 35 (17.3%) 15 (7.2%) 2.697 1.423 – 5.111 0.001 
NO 167 (82.7%) 193 (92.8%) 
 
 
Preterm delivery. 
 
Out of the 410 patients studied, preterm labor occurred in 28.2 % women with UTI 
versus 11.1 % women without UTI. The odds ratio was 3.162 (95% CI: 1.860 – 5.376). 
The difference was statistically significant (p<0.05). 
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Table 26: Preterm delivery versus UTI 
 
PRETERM CASES CONTROLS OR 95% CI P VALUE 
YES 57 (28.2%) 23 (11.1) 3.162 1.860 – 5.376 <0.05 
NO 145 (71.8%) 185 (88.9%) 
 
Chorioamnionitis 
 
There were four cases of chorioamnionitis which occurred among the cases. There were 
no cases of chorioamnionitis among the controls. This showed that urinary tract infection 
during pregnancy predisposed the patient to chorioamnionitis which was statistically 
significant. (p< 0.05) 
 
Pyelonephritis 
 
There were 17 cases of pyelonephritis among the cases. There were no cases of 
pyelonephritis among the controls. Of these 17 cases, 8 had positive growth on blood 
culture, 4 patients had renal angle tenderness, and 5 patients fulfilled criteria for systemic 
inflammatory response syndrome. This showed that there was increased incidence of 
pyelonephritis among the cases as compared to the controls which was statistically 
significant (p<0.05). 
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Postpartum sepsis 
 
Out of the 410 patients studied, postpartum sepsis occurred in 8.9 % women with UTI 
versus 2.4 % women without UTI. The odds ratio was 3.972 (95% CI: 1.446 – 10.912). 
The difference was statistically significant (p=0.003). 
Table 27: Postpartum sepsis and UTI 
 
POSTPARTUM 
SEPSIS 
CASES CONTROLS OR 95% CI P VALUE 
YES 18 (8.9%) 5 (2.4%) 3.972 1.446 – 10.912 0.003 
NO 184 (91.1%) 203 (97.6%) 
 
Intrauterine growth restriction (IUGR) 
 
Out of the 391 patients studied, IUGR occurred in 18.3 % women with UTI versus 11.7 
% women without UTI. The odds ratio was 1.687 (95% CI: 0.959 – 2.969). The 
difference was statistically significant (p=0.046). 
Table 28: IUGR and UTI 
 
IUGR CASES CONTROLS OR 95 % CI P VALUE 
YES 34 (18.3%) 24 (11.7%) 1.687 0.959 – 2.969 0.046 
NO 152 (81.7%) 181 (88.3%) 
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Normal versus Instrumental and Caesarean delivery 
 
Out of the 410 patients studied, instrumental and caesarean delivery occurred in 50 % 
women with UTI versus 44.7 % women without UTI. The odds ratio was 1.237 (95% CI: 
0.839 – 1.823). The difference was not statistically significant (p=0.165). 
SUMMARY OF MATERNAL OUTCOMES 
 
Table 29: SUMMARY OF MATERNAL OUTCOMES 
 CASES CONTROLS OR 95% CI P 
VALUE 
Placental abruption 5 (2.5%) 4 (1.9%) 1.294 0.343- 4.891 0.482 
Gestational hypertension to 
mild pre-eclampsia 
13 (6.4%) 9 (4.3%) 1.521 0.635- 3.641 0.234 
Severe pre eclampsia to 
eclampsia 
11 (5.4%) 10 (4.8%) 1.140 0.473- 2.747 0.472 
Premature rupture of 
membranes 
4 (2%) 8 (3.8%) 0.505 0.150- 1.704 0.205 
Preterm premature rupture of 
membranes 
35 (17.3%) 
 
15 (7.2%) 2.697 1.423- 5.111 0.001 
Preterm delivery 57 (28.2%) 23 (11.1%) 3.162 1.860- 5.376 0.000 
Postpartum sepsis 18 (8.9%) 5 (2.4%) 3.972 1.46- 10.91 0.003 
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Intrauterine growth 
restriction 
34 (18.3%) 24 (11.7%) 1.697 0.959- 2.969 0.046 
Instrumental and caesarean 
deliveries 
101 (50%) 93 (44.7%) 1.237 0.839- 1.823 0.165 
 
FETAL OUTCOMES 
 
LOW BIRTHWEIGHT 
 
Out of 390 patient studied, low birth weight occurred in 30.6 % of pregnant women with 
UTI versus 16.2% women without UTI. The odds ratio was 2.290 (95% CI: 1.409 – 3.722). 
The difference was statistically significant (p=0.001). 
Table 30: Low birth weight and UTI 
 
LOW BIRTH 
WEIGHT 
CASES CONTROLS OR 95% CI P 
VALUE 
YES 57 (30.6%) 33 (16.2%) 2.290 1.409 – 3.722 0.001 
NO 129 (69.4%) 171 (83.8%) 
 
NEONATAL ICU ADMISSION 
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Out of 391 patient studied, neonatal ICU admission occurred in 76.2 % of pregnant women 
with UTI versus 42.1% women without UTI. The odds ratio was 4.406 (95% CI: 2.370 – 
8.189). The difference was statistically significant (p <0.05). 
Table 31: Neonatal ICU admission 
 NICU YES NICU NO OR 95 % CI P VALUE 
CASES 48 (76.2%) 138 (42.1) 4.406 2.370 – 8.189 <0.05 
CONTROLS 15 (23.8%) 190 (57.9%) 
 
APGAR < 7 AT 1 MIN 
 
Out of 391 patient studied, low APGAR occurred in 3.8 % of pregnant women with UTI 
versus 3.4% women without UTI. The odds ratio was 1.106 (95% CI: 0.381 – 3.215). The 
difference was not statistically significant (p=0.533). 
 
APGAR < 7 AT 5 MIN 
 
Out of 391 patient studied, low APGAR occurred in 1.6 % of pregnant women with UTI 
versus 0.5 % women without UTI. The odds ratio was 3.344 (95% CI: 0.345 – 32.434). 
The difference was not statistically significant (p=0.276). 
 
SUMMARY OF FETAL OUTCOMES  
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Table 32: Summary of fetal outcomes 
 
 CASES CONTROLS   OR 95 % CI P 
VALUE 
LOW BIRTH 
WEIGHT 
57 (30.6%) 33 (16.2%) 2.290 1.409- 3.722 0.001 
NICU 
ADMISSION 
48 (25.8%) 15 (7.3%) 4.406 2.370- 8.189 <0.05 
APGAR <7 AT 1 
MIN 
7 (3.8%) 7 (3.4%) 1.106 0.381- 3.215 0.533 
APGAR < 7 AT 5 
MIN 
3 (1.6%) 1 (0.5%) 3.344 0.345- 32.434 0.276 
 
MULTIVARIATE ANALYSIS 
On multivariate analysis, the following factors were statistically significant after adjusting 
for confounding factors. This showed that low maternal education and past history of 
catheterization increases the risk of symptomatic urinary tract infection during pregnancy 
which in turn predisposes to preterm delivery and post-partum sepsis. 
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Table 33: Multivariate analysis 
 
 OR 95% CI P VALUE 
Preterm delivery 3.066 1.797- 5.233 P <0.05 
Low maternal 
education 
1.980 1.096- 3.574 P= 0.023 
Post-partum sepsis 3.585 1.264- 10.171 P= 0.016 
Past history of 
Catheterization 
2.684 1.220- 5.905 P= 0.014 
 
ORGANISMS CAUSING URINARY TRACT INFECTION  
This study showed a total of 214 episodes of urinary tract infection. 11 participants in the 
cases arm had 2 episodes of urinary tract infection and 1 patient had 3 episodes of urinary 
tract infection during their antenatal period.  
Table 34: Recurrent urinary tract infection 
 
NUMBER OF URINARY TRACT 
INFECTION 
NUMBER OF CASES 
1 EPISODE OF URINARY TRACT 
INFECTION 
202 
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2 EPISODES OF URINARY TRACT 
INFECTION 
11 
3 EPISODES OR URINARY TRACT 
INFECTION 
1 
TOTAL 214 
 
The most common organism causing urinary tract infection was E. coli followed by 
Klebsiella. Other organisms causing urinary tract infection were Citrobacter species, non 
fermenting gram negative bacilli, Enterobacter, Serratia, Aeromonas, Enterococcus, 
Streptococci, Staphylococcus species and Pseudomonas.  
 
Table 35: Organisms causing UTI 
 
ORGANISMS NUMBER PERCENTAGE 
E.COLI 115 53.7% 
KLEBSIELLA 43 20.1% 
ENTEROCOCCUS 45 21.02% 
STREPTOCCUS 14 6.5% 
CITROBACTER 9 4.2% 
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STAPHYLOCOCCUS 9 4.2% 
NFGNB 10 4.7% 
PSEUDOMONAS 5 2.3% 
ENTEROBACTER 4 1.9% 
SERRATIA 2 0.93% 
AEROMONAS 1 0.47% 
 
We also looked at the antimicrobial susceptibility pattern of the organisms causing 
urinary tract infection. 40.8% of the E.coli were extended spectrum beta lactamase 
producers. 23.3% of Klebsiella were ESBL producers.  
There was only 1 patient with Enterococcus which was resistant to Ampicillin.  
Staphylococcus species were found to cause 4.2% of urinary tract infection. The species 
cultures included Staphylococcus aureus and Staphylococcus saprophyticus. 
There were 5 patients who grew Pseudomonas species in the urinary culture. All of them 
were susceptible to Piperacillin Tazobactum, Levofloxacin and Cefoperazone sulbactum. 
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DISCUSSION 
Urinary tract infection during pregnancy is associated with adverse maternal and fetal 
outcomes as shown by various studies done. This is potentially a preventable cause for 
adverse maternal and fetal outcomes by early detection and appropriate treatment of 
infection. Most of the studies on urinary tract infection have come from the western 
literature. Therefore, it is necessary to know the prevalence of the same in India and ensure 
early detection and treatment of urinary tract infection.  
This is a cross sectional study which has recruited 410 pregnant women between July 2017 
and August 2018. 9 were multifetal pregnancies. The incidence of pyelonephritis was 8% 
in our institution which was higher than that published in western literature of 0.5 to 2% 
(6).  The increase in incidence of pyelonephritis is due to severe reasons such as increased 
prevalence of symptomatic urinary tract infection in India as compared to Western 
population and referral bias in view of this institution being a tertiary care center. 
This study also looked at risk factors which predisposed to urinary tract infection.  Elderly 
gravida is associated with adverse outcomes (43). In this study there was no statistically 
significant increased risk of UTI in elderly gravida. This could be because there were only 
14 pregnant women who were 35 years of age or older. We also looked at whether teenage 
pregnancy increased the risk of urinary tract infection. Teenage pregnancy is associated 
with numerous adverse outcomes such as preterm delivery, low birth weight and neonatal 
mortality as shown by Chen et al(44).  There were no studies which looked at the 
prevalence of UTI in teenage pregnancy. Our study had 10 patients with teenage pregnancy 
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of which 3 developed symptomatic urinary tract infection. This was not statistically 
significant however. 
Our study also looked at parity and risk of urinary tract infection. Emiru et al had shown 
that parity was not statistically associated with risk of urinary tract infection(10). Our study 
showed that primigravida had increased risk of urinary tract infection which was 
statistically significant with OR of 1.458 (95% CI 0.987- 2.153, p=0.036). Study done by 
Wing et al in 2014, showed that multiparous women had reduced incidence of urinary tract 
infection as compared to nulliparous women (6). This could be attributed to the better 
awareness of pregnancy complications in multiparous women as compared to nulliparous 
women (47). 
Multifetal pregnancy was associated with increased risk of urinary tract infection which 
was consistent with the findings of Dotters-Ketz et al in 2015 which  had shown that 
multifetal pregnancy had increased risk of urinary tract infection with OR of 3.01 (95 % 
CI 2.93 to 3.09) (45). Our study showed similar findings with OR of 8.53 (95% CI of 1.05 
to 68.8, p= 0.04). This could be explained by the higher progesterone levels in multifetal 
pregnancy, increase in size of the renal collecting system when compared to singleton 
pregnancy and by gravid uterus causing compression of the ureters which increases the risk 
for urinary tract infection (45). 
When we looked at the incidence of urinary tract infection as per each trimester, it was 
seen that UTI occurred most commonly in the third trimester. This can be explained by the 
gravid uterus causing obstruction to the genitourinary system and hence predisposing to 
UTI.  
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Study done by Mazor-Dray et al in 2009 looked at 199,093 deliveries. This study showed 
that pregnant women who developed UTI had statistically significant higher number of 
patients who underwent fertility treatment as compared to pregnant women who did not 
develop UTI (41). Our study had 22 patients who conceived following fertility treatment. 
However, there was no statistical significant association between fertility treatment and 
UTI. This could be because of the lower number of pregnant women who were studied in 
this study. There was no association between abortion and risk of urinary tract infection. 
Low maternal education is associated with adverse pregnancy outcomes as shown by study 
done by Muttai et al in Kenya (48).  However, it did not look at urinary tract infection and 
association with maternal education. Emiru et al looked at education as a risk factor of UTI 
and found that there was no statistically significant association between the same. Wing et 
al showed that lower maternal education, which was defined as less than 12 years of formal 
education, was associated with increased risk of UTI with OR of 1.5 (95% CI 1.4- 1.7) (6). 
Our study done showed that low maternal education, which was defined as less than 
completion of high school was associated with increased risk of urinary tract infection with 
OR of 1.834 (95% CI 1.03- 3.24, p <0.05). There was no association between low 
kuppuswamy SES score and adverse maternal outcomes.  
Gestational DM is associated with increased risk of urinary tract infection as shown by 
McMahon et al (11). Our study did not show any statistically significant association. This 
could be because of the early detection of GDM through universal screening, aggressive 
management of uncontrolled diabetes through obstetric medicine clinics and gestational 
DM clinics and careful follow up of patients. 
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Pregestational DM and chronic hypertension did not have statistically significant 
association with risk of urinary tract infection.  
Anemia during pregnancy is associated with adverse outcomes. Anemia increases the risk 
of urinary tract infection has been shown by Schieve et al in 1994 (49). Our study showed 
that hemoglobin less than 11 g/dl is associated with increased risk for urinary tract infection 
with OR of 1.484 (95% CI 0.973- 2.263, p<0.05).  
This study then looked at maternal outcomes secondary to urinary tract infection. There 
was increased incidence of preterm premature rupture of membranes among pregnant 
women with urinary tract infection as compared to pregnant women without urinary tract 
infection in our study and this was statistically significant with OR of 2.697 (95% CI 1.423- 
5.11, p= 0.001). Urinary tract infection predisposes to PPROM has been seen in various 
studies. Mazor-Dray et al in 2009 showed increased risk of PPROM in pregnant women 
with UTI with OR 1.5 (95% CI 1.4- 1.7) and increased incidence of preterm delivery with 
OR 2.1 (95% CI 1.9-2.3, p<0.05) (41). There was increased incidence of preterm delivery 
in our study which was also statistically significant with OR of 3.162 (95% CI 1.860-5.376, 
p<0.05). Pregnant women with urinary tract infection also had increased incidence of post-
partum sepsis ( OR 3.972, 95% CI 1.446- 10.912, p= 0.003) and intrauterine growth 
restriction (OR 1.697, 95% CI 0.959- 2.969, p=0.046) which were all statistically 
significant and similar to study findings of Mazor-Dray et al (41). There was no statistically 
significant difference in the number of normal versus LSCS or Instrumental delivery in 
association with urinary tract infection. This could be because of early detection of UTI 
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and appropriate treatment for the same, lesser number of LSCS that happen in our hospital 
as compared to Western population.  
When we looked at fetal outcomes, low birth weight and neonatal ICU admission were 
increased among pregnant women with urinary tract infection as compared to pregnant 
women without UTI which were statistically significant with low birth weight having OR 
of 2.29 (95% CI 1.409- 3.722, p= 0.001) and neonatal ICU admission having OR of 4.406 
(95% CI 2.370- 8.189, p <0.05).  Increased incidence of low birth weight among pregnant 
women with UTI was shown in numerous studies such as that done by Wing et al, Mazor-
Dray et al, and Schieve et al (6,41,49). UTI predisposed to preterm labor which leads to 
low birth weight and increased neonatal ICU admission for preterm care.  
When multivariate analysis was done, low maternal education and past history of 
catheterization predisposing to symptomatic urinary tract infection were statistically 
significant (OR 1.989, 95% CI 1.096- 3.574, p= 0.023 ; OR 2.684, 95% CI 1.220- 5.905, 
p=0.014) . Preterm delivery and post-partum sepsis were statistically significant in 
multivariate analysis (OR 3.066, 95% CI 1.797- 5.233, p< 0.05; OR 3.585, 95% CI 1.264- 
10.171, p=0.016).  
We then looked at the organisms causing urinary tract infection. Most common organism 
causing UTI was E.coli followed by Klebsiella. The antimicrobial susceptibility data 
showed that 40.8% of the E.coli were extended spectrum beta lactamase producing E.coli 
and 23.3% of the Klebsiella were extended spectrum beta lactamase producing Klebsiella. 
There was no significant difference in outcome of urinary tract infection caused by ESBL 
producing organism versus non ESBL producing organism 
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LIMITATIONS 
There were a few limitations in this study. Firstly, we did not achieve the sample 
size which we intended to, due to slow recruitment. However, to the best of our knowledge 
this would be one of the first studies in CMC, which looked at risk factors, maternal 
outcomes, and fetal outcomes, organisms causing urinary tract infection and antimicrobial 
susceptibility pattern for the same. Therefore, this study, despite its small sample size, 
provides a scaffolding for further research, especially in identifying risk factors, predictors 
and treatment options. 
Secondly, in view of being a tertiary care center, there is referral bias which tends 
to overestimate the adverse maternal and fetal outcomes. 
Thirdly, as we recruited pregnant women after delivery, administrating the 
questionnaire was cumbersome and could have resulted in false reporting by the patient.  
Fourthly, the symptoms seen in urinary tract infection can also be seen in pregnancy 
and during labour which makes it difficult to assess if they are having symptomatic urinary 
tract infection. 
Fifthly, the assessment of family income, and socioeconomic status may not have 
been accurate as patient and family tend to underplay their profession and income so as to 
attain financial support from the institution.  
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CONCLUSIONS 
In conclusion, this cross sectional study done on pregnant women showed that urinary tract 
infection during pregnancy is associated with adverse maternal and fetal outcomes. This 
can ideally be prevented by screening for asymptomatic bacteriuria and early appropriate 
antibiotic therapy to prevent symptomatic urinary tract infection. Patient with risk factors 
for urinary tract infection need to be identified early and precautions need to be taken to 
prevent development of the same.  
 Future research must be aimed at ensuring larger number of patient recruitment with 
emphasis on good follow-up by using the same model as we used in this study. We should 
also look at the incidence of asymptomatic bacteriuria and the adverse maternal and fetal 
outcomes associated with same, as the group has more adverse outcomes as they do not 
seek therapy, given they are asymptomatic.  
In addition, studies must be done to elucidate the pathogenesis for urinary tract infection, 
even though there are proposed theories, but none have been conclusively proven. We must 
perform studies to look at the cytokine and interleukin levels at baseline, end of each 
trimester and following a urinary tract infection.  
In conclusion, early detection and treatment for symptomatic urinary tract infection 
prevents adverse maternal and fetal outcomes and reducing mortality and morbidity. This 
is a preventable cause of mortality. Various actions at the national health policy level need 
to be implemented to prevent the same   
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ANNEXURES 
 
DATA ENTRY FORM 
 
RISK FACTORS 
FERTILITY TREATMENT-  YES 1 / NO 2 
IF YES-  OVULATION INDUCTION1/ICSI2/IVF3/GIFT4/ZIFT5/OTHERS6/MORE THAN ONE7 
IF OTHERS, MENTION  
NUMBER OFABORTIONS                                        NUMBER OF CONSECUTIVE ABORTIONS   
EDUCATIONAL STATUS         ILLITERATE1/ PRIMARY SCHOOL CERTIFICATE2/ MIDDLE SCHOOL 
CERTIFICATE3/ HIGH SCHOOL CERTIFICATE4/ INTERMEDIATE OR POST HIGH SCHOOL DIPLOMA5/ 
GRADUATE OR POST GRADUATE6/ PROFESSIONAL OR HONOURS7. 
OCCUPATION  PROFESSION10/ SEMI PROFESSION6/ CLERICAL, SHOP OWNER, FARMER5/ 
SKILLED4/ SEMISKILLED3/ UNSKILLED2/ UNEMPLOYED1. 
FAMILY MONTHLY INCOME  >/= 42,87612/ 21,438- 42,87510/ 16,078- 21,4376/ 10,719- 16,0774/ 
6,431- 10,7183/ 2,165- 6,4302/ </= 2,1641 
MODIFIED KUPPUSWAMY SES SCALE < 5= LOWER1/ 5-10= UPPER LOWER2/ 11-15= LOWER MIDDLE3/ 
16- 25= UPPER MIDDLE4/ 26-29 = UPPER5 
TRIMESTER AT WHICH UTI OCCURRED    TRIMESTER1/ SECOND TRIMESTER2/ THIRD TRIMESTER  
GENITOURINARY ABNORMALITY  YES1 / NO2
 
PAST HISTORY OF CATHETERIZATION      IN THE LAST 10 YEARS YES 1 / NO 2  
NUMBER OF TIMES CATHETERIZED INDICATION FOR CATHETERIZATION  
DURATION OF EACH CATHETERIZATION  
PAST HISTORY OF UTI IN LAST 10 YEARS YES 1 / NO 2  
YEAR  ORGANISM ISOLATED  SUSCEPTIBILITY PATTERN  
HEMOGLOBIN <  11 1 / <10 2 / <7 3  
T 
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GESTATIONAL DIABETES MELLITUS YES/NO  IF YES OHA1/ INSULIN2/DIET3   
PREGESTATIONAL DIABETES  YES/NO  IF YES OHA1/ INSULIN2/DIET3  
CHRONIC HYPERTENSION  YES/NO 
S 
NO 
ORGANISM 
ISOLATED 
COLONY 
COUNTS 
SUSCEPTIBILITY PATTERN 
1. GNB  AUG  AMI  CEFPERSUL  NITRO  SEPTRAN  GENTA  CEFPOD  CIPRO 
2. ENTEROCOCCUS  NITRO  AMPI  GENTA 
3. STREPTOCOCCI- 
B 
 PENICILLIN  ERYTHROMYCIN 
4.    
MATERNAL OUTCOMES 
PLACENTAL ABRUPTION    YES/NO 
GESTATIONAL HYPERTENSION TO MILD PREECLAMPSIA   YES/NO 
SEVERE PRE ECLAMPSIA TO ECLAMPSIA   YES/NO 
PROM  YES/NO    PRETERM   YES/ NO 
PPROM   YES/ NO   POST PARTUM SEPSIS  YES/ NO 
CHORIOAMNIONITIS  YES/NO 
PYELONEPHRITIS POSITIVE BLOOD CULTURE1/ RENAL ANGLE TENDERNESS2/ SONOLOGY3/ SIRS4 
NORMAL/ INSTRUMENTAL DELIVERY  NORMAL1/ LOW FORCEPS2/ HIGH FORCEPS3/ SUCTION CUP4 
CESAREAN DELIVERY  YES/NO 
ICU ADMISSION   YES/NO 
DURATION OF STAY IN ICU                     INOTROPES 
DURATION OF IN HOSPITAL STAY     
DEATH  YES/NO             IF YES, CAUSE OF DEATH 
FETAL OUTCOMES 
IUGR   YES/NO 
GESTATIONAL AGE AT BIRTH IN WEEKS   
BIRTH WEIGHT IN KG 
APGAR AT   5  MIN   
DEATH   YES/NO   LIVE BORN/ STILL BORN 
NICU ADMISSION  YES1/ NO2 IF YES, REASON    
YES/NO MECHANICAL VENTILATION YES/NO  
1 MIN 
 101 
 
Patient information sheet 
Christian Medical College, Vellore 
Department of General Medicine III 
PATIENT INFORMATION SHEET 
 
Assessment of maternal outcomes and fetal outcomes secondary to urinary tract 
infection in pregnancy 
Purpose of research: 
You are being requested to participate in a study to see the adverse effects of urinary tract 
infection during pregnancy so as to see whether prevention of urinary tract infection 
during pregnancy can improve maternal and fetal outcomes. There is increased risk for 
urinary tract infection during pregnancy due to the body changes that occur during 
pregnancy. Early detection and appropriate treatment of the same may help to reduce the 
adverse maternal and fetal outcomes that can occur.  
 
If you take part what will you have to do? 
If you agree to participate in this study, you will be interviewed to see whether you have 
any risk factors that predispose to urinary tract infection and also to assess the increase in 
expenditure due to UTI. You will also be followed up till delivery to see the number of 
hospital visits required, number of UTIs, what treatment you received,  and to assess 
adverse outcomes that have occurred to you as well as to the baby in case of the same. By 
giving consent, you are also giving permission to access your medical records for this 
study purpose. 
 
What are the risks or benefits to you? 
By participating in this study, you are not expected to have any risks or benefits. The 
study is purely observational, which means that participating in the study will not affect 
the course of your treatment. We are hoping that the results of this study will help us to 
reduce the adverse outcomes of urinary tract infection during pregnancy by early 
detection and appropriate treatment of the same. 
 
Can you withdraw from this study after it starts? 
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Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment at this hospital in any way.  
 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you as it is a purely observational study.  
 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes may be reviewed by people associated with the study, without your additional 
permission, should you decide to participate in this study.  
 
If you have any further questions, please ask  
Dr. Anjely Pulparampil Sebastian 
 Post Graduate Resident 
Department of General Medicine Unit III 
CMC Vellore. 
Ph: 0416 2282039 
Ph: 9751719991 
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Informed consent form 
Informed Consent Form for Subjects 
Study Title: Assessment of maternal outcomes and foetal outcomes secondary to urinary 
tract infection in pregnancy. 
 
Study Number: ____________ 
 
Subject’s Initials:__________________  
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask questions. [  
] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw from 
the trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         
 
Signature:                              Or 
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Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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ETHICAL COMMITTEE AND FUNDS APPROVAL 
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DATA ENTRY SET 
 
 109 
 
 
 110 
 
 
 111 
 
 
 112 
 
 
 113 
 
 
 
 
 
 
 
 
 
 
 
 114 
 
 
 115 
 
 
 116 
 
 
 117 
 
 
 118 
 
 
 119 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
 
 
 121 
 
 
 122 
 
 
 123 
 
 
 124 
 
 
 125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
 
 
 127 
 
 
 128 
 
 
 
 129 
 
 
 
 
 130 
 
 
 131 
 
 
 
 
 
 
 
 
 
